Kroger pharmacies add Zepbound KwikPen
“Our customers and communities want affordable, effective weight-management treatment options with real affordability,” said Colleen Lindholz, group vice president and president of Kroger Health.
Eli Lilly
Zepbound’s growth fuels new employer coverage models
The success of Eli Lilly’s Zepbound is encouraging efforts to expand access to obesity treatments by clarifying pricing and reducing costs.
Zepbound now available in multi-dose KwikPen
Used by millions of patients worldwide, the KwikPen for single-patient use offers a new option for receiving Zepbound.
Lilly picks Pennsylvania for U.S. injectable manufacturing site
The $3.5 billion Lehigh Valley site will develop Lilly's next-generation weight-loss medicines, including retatrutide.
Strive sues Eli Lilly and Novo Nordisk over GLP-1 access
Strive Compounding Pharmacy accuses drugmakers of anti-competitive actions to suppress lawful compounded GLP-1 medications and restrict patient choice.
Eli Lilly briefly tops $1 trillion valuation as GLP-1 demand soars
The drugmaker’s GLP-1 portfolio achieved triple-digit sales growth in Q3, strengthening Lilly’s leadership in the growing weight-loss market.
Trump strikes historic deal to cut drug prices
Prices for Wegovy, Ozempic, and Zepbound drop from over $1,000 to $350 with the new deal. Medicare coverage begins for GLP-1 obesity drugs for the first time.
Lilly to invest over $1.2 billion to expand Puerto Rico facility
The enhanced facility will be among those that will manufacture for orforglipron, Lilly’s first oral, small-molecule GLP-1 receptor agonist.
Lilly unveils 2026 Team USA athletes, expands Milestones into Meaning program
Eli Lilly announced its Team USA lineup for the 2026 Winter Games. The company will also expand its Milestones into Meaning program.
Lilly taps Shaquille O’Neal to spotlight sleep apnea
“Moderate-to-severe obstructive sleep apnea is more than just snoring – it’s a serious condition and it deserves serious attention,” O’Neal said.
Lilly to buy Adverum Biotechnologies
The acquisition strengthens Lilly’s genetic medicine pipeline and expands its footprint in ophthalmology.
Lilly’s oral GLP-1 drug nears global filing
Lilly’s oral GLP-1 pill helped patients lose 22 pounds and lower A1C in a Phase 3 trial, with global filings planned this year.
Lilly to expand collaboration with Purdue University
Will include a planned investment up to a $250 million to accelerate pharmaceutical innovation.
LillyDirect platform expands to improve access to Alzheimer's care
Eli Lilly and Company enhances digital healthcare offerings to address delays in diagnosis and treatment.